Download PDF
CC BY-NC-ND 4.0 · J Lab Physicians 2023; 15(03): 419-424
DOI: 10.1055/s-0043-1761928
Original Article

In-vitro Activity of Isepamicin against Gram-negative Bacteria in Comparison to Other Aminoglycosides Routinely used at a Teaching Hospital in Northern India

Tasneem Siddiqui 
1   Department of Microbiology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India
,
Mitra Kar 
1   Department of Microbiology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India
,
Akanksha Dubey 
1   Department of Microbiology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India
,
Sangram Singh Patel 
1   Department of Microbiology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India
,
Chinmoy Sahu 
1   Department of Microbiology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India
› Author Affiliations Funding None.
› Further Information
Also available at
   Permissions and Reprints

Abstract

Background Isepamicin is a 1-N-S-a-hydroxy-b-aminopropionyl derivative of gentamicin B and the spectrum of pathogenic microorganisms covered by it and its effectiveness is similar to that of amikacin except the action of aminoglycoside inhibitor enzymes is ineffectual on it.

Material and Methods We performed a prospective study in the Bacteriology section of the Department of Microbiology at a 1,600-bedded hospital in Northern India from Jan 2022 to March 2022. Isepamicin was tested for susceptibility against gram-negative bacteria, identified by routine biochemicals and matrix-assisted-desorption/ionization –time of flight-mass spectrometry (MALDI-TOF-MS) assay. The antibiotic susceptibility testing for each of the isolates was performed by Kirby Bauer's disc diffusion method, according to the CLSI 2019 guidelines.

Results The majority of isolates were obtained from blood samples (50, 39.1%). Among the non-inducible Enterobacteriaceae, Escherichia coli was least susceptible to amikacin (8/27, 29.63%) and most susceptible to isepamicin (18/27, 66.67%). Klebsiella pneumoniae followed the same pattern of susceptibility as E. coli and was least susceptible to Amikacin (20/46, 43.48%) and most susceptible to isepamicin (24/46, 52.17%). Enterobacter cloacae (6/7, 85.71%) was most susceptible to both amikacin and isepamicin, followed by 71.43% (5/7, 71.43%) susceptibility to gentamicin and tobramycin each. Enterobacter aerogenes was equally 53.33% (8/15) susceptible to all antibiotics. Pseudomonas aeruginosa was the most susceptible isolate to all antibiotics (18/21, 85.71%).

Conclusion Isepamicin is a potential antimicrobial agent for treating an array of gram-negative bacteria-associated infections and shows better in vitro activity than older aminoglycoside agents.

Keywords

isepamicin - MALDI-TOF-MS - gram-negative bacteria - gentamicin B - antimicrobial agents

Authors' Contributions

Protocol development: T.S., A.D., C.S.


Data collection: A.D., T.S. Data analysis: C.S., S.S.P. Supervision: C.S., S.S.P.


Writing - original draft: M.K., A.D. Writing – review & editing: M.K., A.D., T.S., C.S., S.S.P.


All authors read and approved the final version of the manuscript.


Consent for Publication

All individuals have given consent to participate in the study.


Ethical Statement

The study protocol was approved by the institutional Ethics Committee of Sanjay Gandhi Postgraduate Institute of Medical Sciences (Reference number 2020–100-EMP-EXP-16)




Publication History

Article published online:
22 March 2023

© 2023. The Indian Association of Laboratory Physicians. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Belgian Isepamicin Multicenter Study Group. Comparative in vitro activity of isepamicin and other antibiotics against gram-negative bacilli from intensive care units (ICU) in Belgium. Acta Clin Belg 2001; 56 (05) 307-315
    CrossrefPubMedGoogle Scholar
  • 2 Mingeot-Leclercq MP, Glupczynski Y, Tulkens PM. Aminoglycosides: activity and resistance. Antimicrob Agents Chemother 1999; 43 (04) 727-737
    CrossrefPubMedGoogle Scholar
  • 3 Miller GH, Sabatelli FJ, Naples L, Hare RS, Shaw KJ. The Aminoglycoside Resistance Study Groups. The most frequently occurring aminoglycoside resistance mechanisms–combined results of surveys in eight regions of the world. J Chemother 1995; 7 (Suppl. 02) 17-30
    PubMedGoogle Scholar
  • 4 Miller GH, Sabatelli FJ, Naples L, Hare RS, Shaw KJ. The Aminoglycoside Resistance Study Groups. The changing nature of aminoglycoside resistance mechanisms and the role of isepamicin–a new broad-spectrum aminoglycoside. J Chemother 1995; 7 (Suppl. 02) 31-44
    PubMedGoogle Scholar
  • 5 Miller GH, Sabatelli FJ, Hare RS. et al. The most frequent aminoglycoside resistance mechanisms–changes with time and geographic area: a reflection of aminoglycoside usage patterns? Aminoglycoside Resistance Study Groups. Clin Infect Dis 1997; 24 (Suppl. 01) S46-S62
    CrossrefPubMedGoogle Scholar
  • 6 Vanhoof R, Nyssen HJ, Van Bossuyt E, Hannecart-Pokorni E. Aminoglycoside Resistance Study Group. Aminoglycoside resistance in gram-negative blood isolates from various hospitals in Belgium and the Grand Duchy of Luxembourg. J Antimicrob Chemother 1999; 44 (04) 483-488
    CrossrefPubMedGoogle Scholar
  • 7 Goering RV, Sanders CC, Sanders WE. In vivo analysis of structure-activity relationships among four aminoglycosides: gentamicin, netilmicin, 1-N HAPA gentamicin B, and amikacin. Curr Ther Res Clin Exp 1979; 26: 329-341
    Google Scholar
  • 8 Nagabhushan TL, Cooper AB, Tsai H, Daniels PJ, Miller GH. The syntheses and biological properties of 1-N-(S-4-amino-2-hydroxybutyryl)-gentamicin B and 1-N-(S-3-amino-2-hydroxypropionyl)-gentamicin B. J Antibiot (Tokyo) 1978; 31 (07) 681-687
    CrossrefPubMedGoogle Scholar
  • 9 Oshitani H, Kawai S, Kobayashi H. Experimental and clinical studies of HAPA-B. Chemother 1985; 33: 201-205
    Google Scholar
  • 10 Takumida M, Nishida I, Nikaido M, Hirakawa K, Harada Y, Bagger-Sjöbäck D. Effect of dosing schedule on aminoglycoside ototoxicity: comparative cochlear ototoxicity of amikacin and isepamicin. ORL J Otorhinolaryngol Relat Spec 1990; 52 (06) 341-349
    CrossrefPubMedGoogle Scholar
  • 11 Over U, Gür D, Unal S, Miller GH. Aminoglycoside Resistance Study Group. The changing nature of aminoglycoside resistance mechanisms and prevalence of newly recognized resistance mechanisms in Turkey. Clin Microbiol Infect 2001; 7 (09) 470-478
    CrossrefPubMedGoogle Scholar
  • 12 Cheng NC, Hsueh PR, Liu YC. et al. In vitro activities of tigecycline, ertapenem, isepamicin, and other antimicrobial agents against clinically isolated organisms in Taiwan. Microb Drug Resist 2005; 11 (04) 330-341
    CrossrefPubMedGoogle Scholar
  • 13 Maraki S, Samonis G, Karageorgopoulos DE, Mavros MN, Kofteridis D, Falagas ME. In vitro antimicrobial susceptibility to isepamicin of 6,296 Enterobacteriaceae clinical isolates collected at a tertiary care university hospital in Greece. Antimicrob Agents Chemother 2012; 56 (06) 3067-3073
    CrossrefPubMedGoogle Scholar
  • 14 Falagas ME, Kasiakou SK. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis 2005; 40 (09) 1333-1341
    CrossrefPubMedGoogle Scholar
  • 15 Falagas ME, Kastoris AC, Kapaskelis AM, Karageorgopoulos DE. Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum beta-lactamase producing, Enterobacteriaceae infections: a systematic review. Lancet Infect Dis 2010; 10 (01) 43-50
    CrossrefPubMedGoogle Scholar
  • 16 Wayne PA. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing: Twenty-third informational supplement. Clinical and Laboratory Standards Institute. CLSI document M100–S29; USA; 2019
    Google Scholar
  • 17 Martin MA. Epidemiology and clinical impact of gram-negative sepsis. Infect Dis Clin North Am 1991; 5 (04) 739-752
    CrossrefPubMedGoogle Scholar
  • 18 Bryan CS, Reynolds KL, Brenner ER. Analysis of 1,186 episodes of gram-negative bacteremia in non-university hospitals: the effects of antimicrobial therapy. Rev Infect Dis 1983; 5 (04) 629-638
    CrossrefPubMedGoogle Scholar
  • 19 Tsai TY, Chang SC, Hsueh PR, Feng NH, Wang JT. In vitro activity of isepamicin and other aminoglycosides against clinical isolates of Gram-negative bacteria causing nosocomial bloodstream infections. J Microbiol Immunol Infect 2007; 40 (06) 481-486
    PubMedGoogle Scholar
  • 20 Craig WA. Once-daily versus multiple-daily dosing of aminoglycosides. J Chemother 1995; 7 (Suppl. 02) 47-52
    PubMedGoogle Scholar
  • 21 Siu LK. Antibiotics: action and resistance in gram-negative bacteria. J Microbiol Immunol Infect 2002; 35 (01) 1-11
    PubMedGoogle Scholar
  • 22 Fauvelle F, Coulaud JM, Lecointre K, Tardy D, Poussel JF, Trape G. Comparison of two methods to obtain a desired first isepamicin peak in intensive care patients. Fundam Clin Pharmacol 2001; 15 (02) 151-156
    CrossrefPubMedGoogle Scholar
  • 23 Jones RN. Isepamicin (SCH 21420, 1-N-HAPA gentamicin B): microbiological characteristics including antimicrobial potency of spectrum of activity. J Chemother 1995; 7 (Suppl. 02) 7-16
    PubMedGoogle Scholar
  • 24 Miller GH, Chiu PJ, Waitz JA. Biological activity of SCH 21420, the 1-N-S-alpha-hydroxy-beta-aminopropionyl derivative of gentamicin B. J Antibiot (Tokyo) 1978; 31 (07) 688-696
    CrossrefPubMedGoogle Scholar
  • 25 Verbist L. Incidence of multi-resistance in gram-negative bacterial isolates from intensive care units in Belgium: a surveillance study. Scand J Infect Dis Suppl 1991; 78 (Suppl. 78) 45-53
    Google Scholar
  • 26 Glupczynski Y, Delmée M, Goossens H, Struelens M. on behalf of a Belgian Multicenter study group. A multicenter survey of antimicrobial resistance in gram-negative isolates from Belgian intensive care units in 1994–1995. Acta Clin Belg 1998; 53 (01) 35-45
    CrossrefPubMedGoogle Scholar
  • 27 Vincent JL, Bihari DJ, Suter PM. et al; EPIC International Advisory Committee. The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. JAMA 1995; 274 (08) 639-644
    CrossrefPubMedGoogle Scholar
  • 28 Spencer RC. Predominant pathogens found in the European Prevalence of Infection in Intensive Care Study. Eur J Clin Microbiol Infect Dis 1996; 15 (04) 281-285
    CrossrefPubMedGoogle Scholar
  • 29 Jarlier V, Fosse T, Philippon A. Antibiotic susceptibility in aerobic gram-negative bacilli isolated in intensive care units in 39 French teaching hospitals (ICU study). Intensive Care Med 1996; 22 (10) 1057-1065
    CrossrefPubMedGoogle Scholar
  • 30 Küçükates¸ E, Kansız E, Gültekin N. Resistance to isepamicin, amikacin and gentamicin in gram-negative bacteria. Infeks Derg 2007; 21: 21-25
    Google Scholar